Loading...
Please wait, while we are loading the content...
Similar Documents
Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment.
| Content Provider | Europe PMC |
|---|---|
| Author | Jou, Eric Chaudhury, Natasha Nasim, Fizza |
| Editor | Okada, Seiji |
| Abstract | Cancer is the leading cause of death globally superseded only by cardiovascular diseases, and novel strategies to overcome therapeutic resistance against existing cancer treatments are urgently required. Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells with potent immunosuppressive capacity against well-established anti-tumour effectors such as natural killer cells (NK cells) and T cells thereby promoting cancer initiation and progression. Critically, MDSCs are readily identified in almost all tumour types and human cancer patients, and numerous studies in the past decade have recognised their role in contributing to therapeutic resistance against all four pillars of modern cancer treatment, namely surgery, chemotherapy, radiotherapy and immunotherapy. MDSCs suppress anti-tumour immunity through a plethora of mechanisms including the well-characterised arginase 1 (Arg1), inducible nitric oxide synthase (iNOS) and reactive oxygen species (ROS)-mediated pathways, along with several other more recently discovered. MDSCs are largely absent in healthy homeostatic states and predominantly exist in pathological conditions, making them attractive therapeutic targets. However, the lack of specific markers identified for MDSCs to date greatly hindered therapeutic development, and currently there are no clinically approved drugs that specifically target MDSCs. Methods to deplete MDSCs clinically and inhibit their immunosuppressive function will be crucial in advancing cancer treatment and to overcome treatment resistance. This review provides a detailed overview of the current understandings behind the mechanisms of MDSC-mediated suppression of anti-tumour immunity, and discusses potential strategies to target MDSC immunosuppressive mechanisms to overcome therapeutic resistance. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10918238&blobtype=pdf |
| Volume Number | 5 |
| DOI | 10.37349/etat.2024.00212 |
| PubMed Central reference number | PMC10918238 |
| Issue Number | 1 |
| PubMed reference number | 38464388 |
| Journal | Exploration of Targeted Anti-tumor Therapy [Explor Target Antitumor Ther] |
| e-ISSN | 26923114 |
| Language | English |
| Publisher | Open Exploration Publishing |
| Publisher Date | 2024-02-28 |
| Access Restriction | Open |
| Rights License | This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. © The Author(s) 2024. |
| Subject Keyword | Tumor microenvironment cancer therapy preclinical models immunotherapy myeloid-derived suppressor cell myeloid cells immunosuppression |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Cancer Research |
